Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) was featured on the latest episode of The BioMedWire Podcast, where co-founder and executive co-chair Anthony Durkacz discussed the company's lead drug candidate, Lucid-MS, and its commercial product unbuzzd. Durkacz emphasized that Lucid-MS is being developed to address mobility loss associated with multiple sclerosis by targeting nerve damage, an area he believes remains unmet by currently available treatments.
Lucid-MS is a patented new chemical entity that has shown the ability to prevent and reverse myelin degradation in preclinical models. Myelin degradation is the underlying mechanism of multiple sclerosis, a chronic neurodegenerative disease that affects millions worldwide. The upcoming Phase 2 clinical trial for Lucid-MS will be the first study to evaluate the drug candidate in multiple sclerosis patients, following Phase 1 testing in healthy volunteers. This trial represents a critical step in demonstrating the drug's efficacy in the target patient population.
In addition to its pipeline, Quantum BioPharma has commercialized unbuzzd, an alcohol metabolism product designed to accelerate the breakdown of alcohol in the blood. unbuzzd is currently available in the U.S. market through Unbuzzd Wellness Inc., a company spun out by Quantum and led by industry veterans. Quantum retains a 19.84% ownership stake in Unbuzzd as of March 31, 2026, and is entitled to royalty payments of 7% of sales from unbuzzd until total payments reach $250 million. After that threshold, the royalty drops to 3% in perpetuity. Quantum also retains 100% of the rights to develop similar products or alternative formulations for pharmaceutical and medical uses.
The company's focus on both therapeutic and commercial products positions it to address significant unmet medical needs while generating revenue streams. Multiple sclerosis affects approximately 2.8 million people globally, and current treatments often fail to address mobility loss caused by nerve damage. If Lucid-MS proves successful in Phase 2 trials, it could offer a new option for patients with limited alternatives. Meanwhile, unbuzzd targets alcohol misuse, a widespread public health issue, with a product that helps the body metabolize alcohol more quickly.
Investors can find the latest news and updates relating to QNTM in the company's newsroom at https://ibn.fm/QNTM. The full press release and podcast are available at https://ibn.fm/8sLvp. Quantum BioPharma is dedicated to building a portfolio of innovative assets for challenging neurodegenerative and metabolic disorders, as well as alcohol misuse disorders.
